John Cunningham Virus‐induced Cerebellar Granular Cell Neuronopathy in a Patient With MS Treated With Natalizumab
Increased John Cunningham Virus Seroconversion Rates Seen in a Southern Hemisphere International Cohort of Natalizumab Treated Patients (2291)
Leucoencefalopatía multifocal progresiva causada por el virus John Cunningham en un paciente con esclerosis múltiple remitente-recurrente. A propósito de un caso
Structural vaccinology, molecular simulation and immune simulation approaches to design multi-epitopes vaccine against John Cunningham virus
The incidence and pathogenic role of John Cunningham Virus in patients with chosen neurologic diseases